Harry Durr is an experienced Executive Sales Director at Gilead Sciences, where they currently lead the national sales team for Hepatitis B and are a core member of the Hepatitis D launch strategy team. With a strong background in the biotechnology industry, Harry previously built and managed Gilead's HCV commercial team, launching four HCV medications and generating $15 billion in sales. They have also held leadership roles at Schering-Plough, where their expertise in sales analytics contributed to strategic decision-making. Harry earned a Bachelor of Science in Marketing/Finance from Duquesne University.
This person is not in any teams
This person is not in any offices